Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year (YOY) increase in revenues, excluding foreign exchange effects, to USD 6.4 billion.
Global Performance
Globally, Women’s Health revenues rose 5% YOY to USD 1.78 billion, primarily driven by a 17% growth in Nexplanon (etonogestrel implant) sales, which reached USD 963 million. Jada, a medical device acquired from Alydia Health for preventing abnormal postpartum uterine bleeding or hemorrhage, generated USD 61 million in sales after a 40% expansion.
Biosimilars Business
Organon’s Biosimilars business continued to perform well, growing by 12% YOY to USD 662 million. This growth was driven by the uptake of Organon’s Humira generic Hadlima (adalimumab), which entered the US market from July 2023. Hadlima generated USD 100 million in sales in the US and USD 142 million globally in 2024. However, Organon’s Remicade biosimilar Renflexis (infliximab) and Herceptin biosimilar Ontruzant (trastuzumab) saw a 1% and 9% YOY decline to USD 274 million and USD 141 million respectively, with product maturity cited as the main cause.
Established Brands
Established Brands maintained steady performance with USD 3.849 billion in revenues, a 2% YOY increase, with the negative impact of pricing policies partially offset by product sales.
Regional Performance
Organon’s regional performance in 2024 was as follows:
| Area | 2024 revenues (USD, mil.) | 2023 revenues (USD, mil.) |
|---|---|---|
| Europe and Canada | 1,763 | 1,673 |
| United States | 1,572 | 1,478 |
| Asia Pacific and Japan | 1,050 | 1,129 |
| China | 847 | 864 |
| LatAm, MiddleEast, Russia & Africa | 1,034 | 965 |
| Other | 137 | 154 |
Leave a Reply